5 articles
Attachment and Entry (reactome R-HSA-9678110)
Attachment and Entry (R-HSA-9678110) is a Reactome pathway for SARS-CoV-1 attachment to human cells: spike S1 binds ACE2, S2 mediates fusion, cathepsin L or TMPRSS2 cleavage activates entry, ending in genome uncoating.
Attachment and Entry (reactome R-HSA-9694614)
Attachment and Entry (R-HSA-9694614) is a Reactome pathway for SARS-CoV-2 entry into human cells: spike-ACE2 binding, proteolytic activation by cathepsin L, TMPRSS2, or furin, fusion or endocytosis, and nucleocapsid release.
Enfuvirtide
Enfuvirtide, also known as T-20 or Fuzeon, is a 36-amino-acid peptide that blocks HIV-1 entry into cells, FDA-approved in 2003 as the first fusion inhibitor and given by twice-daily injection.
Neutralizing antibody
Neutralizing antibody: an antibody that blocks viral entry into cells; measured by live-virus (PRNT, CPE) and pseudovirus assays, used as a correlate of protection and as therapeutic and prophylactic antiviral agents.
SARS-CoV-2 Infection
SARS-CoV-2 infection: entry of the coronavirus SARS-CoV-2 (COVID-19 virus) into human cells via spike-ACE2 binding, replication in double membrane vesicles, immune evasion, transmission, and post-acute sequelae.